Fig. 1
From: m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation
Ocular melanoma exhibited decreased m6A levels, which was associated with poor prognosis. a An m6A RNA methylation assay revealed the m6A content in tumor and adjacent normal tissues. For ocular melanoma, n = 10, for normal melanocyte, n = 4, ***p < 0.001. b, c METTL3 and ALKBH5 expression in normal and tumor tissues. B: METTL3 and ALKBH5 expression according to IF analysis. Scale bar: left panel, 100 μm; right panel, 20 μm. C: Statistical results of METTL3 and ALKBH5 expression in normal and tumor tissues. *p < 0.05, ***p < 0.001. d Kaplan-Meier curves of tumor recurrence showing the difference between ocular melanoma patients with low and high METTL3 levels. n = 54, log rank test, p < 0.05. e The expression of METTL3 in patients at AJCC stages T1 to T4. f Kaplan-Meier curves of tumor recurrence showing the difference between ocular melanoma patients with low and high ALKBH5 levels. n = 55, log rank test, p < 0.05. g The expression of ALKBH5 in patients at AJCC stages T1 to T4. h The m6A RNA methylation assay revealed the m6A content in PIG1 cells and ocular melanoma cells. Error bars indicate the mean ± SEM, n = 3, *p < 0.05. i Western blot showing METTL3 and ALKBH5 expression in normal melanocytes and orbital melanoma cells. The METTL3 signal was quantified and normalized to that of β-actin